Enis Aboalhasan
Ashkelon, D, Israel
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Dapagliflozin versus sacubitril-valsartan for heart failure with mildly reduced or preserved ejection fraction.
Journal: Frontiers in pharmacology
Published: December 18, 2023
Dapagliflozin versus empagliflozin in patients with chronic kidney disease.
Journal: Frontiers in pharmacology
Published: May 23, 2023
Effect of Dapagliflozin Versus Empagliflozin on Cardiovascular Death in Patients with Heart Failure Across the Spectrum of Ejection Fraction: Cost per Outcome Analysis.
Journal: American journal of cardiovascular drugs : drugs, devices, and other interventions
Published: March 13, 2023
Liraglutide versus semaglutide for weight reduction-a cost needed to treat analysis.
Journal: Obesity (Silver Spring, Md.)
Published: November 02, 2022
Tirzepatide versus semaglutide for weight loss in patients with type 2 diabetes mellitus: A value for money analysis.
Journal: Diabetes, obesity & metabolism
Published: October 17, 2022
Aspirin with Low-Dose Ticagrelor or with Low-Dose Rivaroxaban for Secondary Prevention: A Cost per Outcome Analysis.
Journal: American journal of cardiovascular drugs : drugs, devices, and other interventions
Published: July 01, 2022
Oral versus subcutaneous semaglutide for prevention of major adverse cardiovascular events: cost per outcome analysis of SUSTAIN-6 and PIONEER-6.
Journal: Postgraduate medicine
Published: June 15, 2022
Usefulness of Empagliflozin Versus Oral Semaglutide for Prevention of Cardiovascular Mortality in Patients With Type 2 Diabetes Mellitus.
Journal: The American journal of cardiology
Published: November 07, 2021
Dapagliflozin Versus Sacubitril-Valsartan to Improve Outcomes of Patients with Reduced Ejection Fraction and Diabetes Mellitus.
Journal: American journal of cardiovascular drugs : drugs, devices, and other interventions
Published: September 28, 2021
Usefulness of Sodium-Glucose Cotransporter 2 Inhibitors for Primary Prevention of Heart Failure in Patients With Type 2 Diabetes Mellitus.
Journal: The American journal of cardiology
Published: December 12, 2020
Dapagliflozin vs. sacubitril-valsartan for prevention of heart failure events in non-diabetic patients with reduced ejection fraction: a cost per outcome analysis.
Journal: European journal of preventive cardiology
Published: September 18, 2020
Icosapent Ethyl for Primary Versus Secondary Prevention of Major Adverse Cardiovascular Events in Hypertriglyceridemia: Value for Money Analysis.
Journal: The American journal of medicine
Published: August 18, 2020
Last Updated: 09/26/2026